This cancer-fighting biotech wants to be our next household name
Telix shares have returned more than 1060 per cent since listing in 2017, but the stock has also felt volatility as investors sold off the biotech sector heavily post-pandemic. “Last year was brutal for biotech,” Behrenbruch…